Title |
Determination of Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Reverse Transcriptase Multiplex Ligation-Dependent Probe Amplification Classifier A CALYM Study
|
---|---|
Published in |
The Journal of Molecular Diagnostics, October 2017
|
DOI | 10.1016/j.jmoldx.2017.07.007 |
Pubmed ID | |
Authors |
Victor Bobée, Philippe Ruminy, Vinciane Marchand, Pierre-Julien Viailly, Ahmad Abdel Sater, Liana Veresezan, Fanny Drieux, Caroline Bérard, Elodie Bohers, Sylvain Mareschal, Sydney Dubois, Jean-Philippe Jais, Karen Leroy, Martin Figeac, Jean-Michel Picquenot, Thierry Jo Molina, Gilles Salles, Corinne Haioun, Hervé Tilly, Fabrice Jardin |
Abstract |
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma. It includes three major subtypes termed germinal center B-cell-like, activated B-cell-like, and primary mediastinal B-cell lymphoma. With the emergence of novel targeted therapies, accurate methods capable of interrogating this cell-of-origin classification should soon become essential in the clinics. To address this issue, we developed a novel gene expression profiling DLBCL classifier based on reverse transcriptase multiplex ligation-dependent probe amplification. This assay simultaneously evaluates the expression of 21 markers, to differentiate primary mediastinal B-cell lymphoma, activated B-cell-like, germinal center B-cell-like, and also Epstein-Barr virus-positive DLBCLs. It was trained using 70 paraffin-embedded biopsies and validated using >160 independent samples. Compared with a reference classification established from Affymetrix U133 + 2 data, reverse transcriptase multiplex ligation-dependent probe amplification classified 85.0% samples into the expected subtype, comparing favorably with current diagnostic methods. This assay also proved to be highly efficient in detecting the MYD88 L265P mutation, even in archival paraffin-embedded tissues. This reliable, rapid, and cost-effective method uses common instruments and reagents and could thus easily be implemented into routine diagnosis workflows, to improve the management of these aggressive tumors. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 8 | 42% |
France | 3 | 16% |
Bahrain | 1 | 5% |
Spain | 1 | 5% |
Unknown | 6 | 32% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 15 | 79% |
Practitioners (doctors, other healthcare professionals) | 2 | 11% |
Scientists | 1 | 5% |
Science communicators (journalists, bloggers, editors) | 1 | 5% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 39 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 9 | 23% |
Student > Bachelor | 6 | 15% |
Student > Master | 4 | 10% |
Professor > Associate Professor | 3 | 8% |
Student > Ph. D. Student | 2 | 5% |
Other | 5 | 13% |
Unknown | 10 | 26% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 15 | 38% |
Agricultural and Biological Sciences | 8 | 21% |
Biochemistry, Genetics and Molecular Biology | 3 | 8% |
Mathematics | 1 | 3% |
Unspecified | 1 | 3% |
Other | 1 | 3% |
Unknown | 10 | 26% |